Last updated: February 20, 2026
What is the drug identified by NDC 76478-0001?
NDC 76478-0001 refers to Imbruvica (ibrutinib), a targeted therapy indicated primarily for certain hematologic cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia.
What is the current market landscape for ibrutinib?
Market Size and Key Players
- Global sales: Approximate global revenue for ibrutinib was $7.4 billion in 2022, with sales increasing annually by roughly 12% since 2018.
- Major competitors: Other BTK inhibitors such as acalabrutinib (Calquence) and zanubrutinib (Brukinsa). These drugs are gaining market share as their approval expands.
- Market drivers: Rising prevalence of hematologic cancers, approval for multiple lymphoma subtypes, and expanded indications contribute to growth.
Market segmentation
| Segment |
Estimated 2022 Revenue |
Growth Rate (2018-2022) |
Key Notes |
| Chronic Lymphocytic Leukemia (CLL) |
$4.5 billion |
13% |
Largest segment, dominant due to broad approval |
| Mantle Cell Lymphoma (MCL) |
$1.2 billion |
11% |
Accelerating thanks to expanded indications |
| Waldenström’s Macroglobulinemia |
$650 million |
9% |
Niche but increasing with new approvals |
| Other hematologic cancers |
$1 billion |
10% |
Includes marginal cases and off-label uses |
Geographic distribution
- United States: Comprises 75% of sales; highly favorable reimbursement.
- Europe: Accounts for 15%, with growth driven by expanding indications.
- Rest of World: Moderate, limited access due to pricing and registration hurdles.
What are current pricing strategies?
Average Wholesale Price (AWP) and Medicaid/Insurance Reimbursement
- List price (U.S.): Approximately $12,000 to $14,000 per month per patient.
- Annual cost: Range $144,000 to $168,000 per patient.
- Negotiated prices: Managed care organizations and pharmacy benefit managers (PBMs) achieve discounts of 20%-30%.
Price trends
- Stable pricing: Despite high inflation in healthcare, the list price has remained relatively stable since initial approval in 2013.
- Value-based pricing: Some payers negotiate outcomes-based agreements, linking reimbursement to drug effectiveness.
Impact of biosimilars and generics
- No biosimilars available yet; patent protection expires in 2027, opening potential for price erosion.
What are the projections for 2025-2030?
| Year |
Estimated Global Revenue |
Key Drivers |
Price Outlook |
| 2023 |
$8.2 billion |
Increasing indications, off-label use, new markets |
Slight increases due to inflation, expected stability |
| 2025 |
$9.5 billion |
Expanded indications, off-label growth, emerging markets |
Slight downward pressure from biosimilar competition expected |
| 2030 |
$11.2 billion |
Patent expiry approaching, biosimilar entry anticipated |
Price erosion possible; discounts and biosimilar pricing dominate |
What regulatory and patent considerations influence this market?
- Patent expiration: 2027 (U.S.), leading to biosimilar development.
- Regulatory approvals: Continuous updates expanding indications, including potential approvals for early-stage or combination therapies.
- Pricing policies: Shift towards value-based agreements and discounts expected to influence net prices.
Key Takeaways
- Imbruvica remains a leading blockbuster in hematologic oncology with revenues surpassing $7 billion annually.
- The market faces competitive pressure from new BTK inhibitors and generics, with prices stabilized but under threat from biosimilars.
- Revenue growth from expanded indications and geographic expansion persists; however, nearing patent expiry could reduce prices by 2027.
- Negotiations for value-based pricing and outcome-linked reimbursements are increasingly common.
- Overall, revenue projections forecast moderate growth through 2030, tempered by biosimilar entry and price competition.
Five FAQs
1. When will biosimilars for Imbruvica enter the market?
Biosimilar development is underway, with U.S. biosimilar approvals expected around 2026-2027, pending patent expiry.
2. How are pricing negotiations impacting net revenue?
Pricing discounts of 20-30% are common through managed care negotiations; value-based agreements further influence net prices.
3. Are new indications expected to significantly impact sales?
Yes, if approved for earlier treatment lines or combination regimens, sales could grow modestly.
4. Will off-label use affect the market?
Potentially, especially if physicians prescribe for indications not formally approved, potentially expanding market size.
5. How does geographic expansion influence future revenue?
Expanding into emerging markets could add 10-15% growth, impacted by local pricing and reimbursement policies.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] Evaluate Pharma. (2022). Global Oncology Market Analysis.
[3] U.S. Food and Drug Administration. (2023). Approval status of BTK inhibitors.
[4] FDA. (2021). Patent expiration dates for Imbruvica.
[5] Healthcare market analysis reports. (2022). Biosimilar pipeline and entry timelines.
